ijms-logo

Journal Browser

Journal Browser

Navigating Precision Oncology: Integrating Biomarkers into Clinical Practice

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 1189

Special Issue Editors


E-Mail Website
Guest Editor
First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Interests: gastrointestinal cancer; immunotherapy; autoimmune liver disease; inflammatory bowel disease

Special Issue Information

Dear Colleagues,

In the realm of cancer research, advances across the board continue to unravel the intricate molecular mechanisms that underlie cancer pathogenesis. Tumor molecular profiling has opened new avenues for personalized and effective therapies, significantly impacting the clinical outcomes of patients.

The application of molecular techniques in cancer diagnosis has the potential to revolutionize current disease detection and management approaches. Novel and sensitive molecular markers, often acquired through non-invasive procedures, offer the prospect of mass screening, which would enable early disease diagnosis. The identification of tumor molecular subtypes aids in assessing disease severity and progression, guiding further diagnostic and treatment interventions, and predicting prognosis.

In this Special Issue, we invite research contributions focused on the implementation of molecular techniques for risk assessment, early diagnosis, molecular typing, prediction of biological behaviour, evaluation of prognosis, and drug screening in malignant tumours.

Prof. Dr. Stamatios E. Theocharis
Dr. Stavros P. Papadakos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • molecular biomarkers
  • pathogenesis
  • treatment
  • precision medicine
  • personalized treatment

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

28 pages, 2387 KiB  
Review
The Clinical Relevance of the EPH/Ephrin Signaling Pathway in Pediatric Solid and Hematologic Malignancies
by Elena Chatzikalil, Ioanna E. Stergiou, Stavros P. Papadakos, Ippokratis Konstantinidis and Stamatios Theocharis
Int. J. Mol. Sci. 2024, 25(7), 3834; https://doi.org/10.3390/ijms25073834 - 29 Mar 2024
Viewed by 937
Abstract
Pediatric neoplasms represent a complex group of malignancies that pose unique challenges in terms of diagnosis, treatment, and understanding of the underlying molecular pathogenetic mechanisms. Erythropoietin-producing hepatocellular receptors (EPHs), the largest family of receptor tyrosine kinases and their membrane-tethered ligands, ephrins, orchestrate short-distance [...] Read more.
Pediatric neoplasms represent a complex group of malignancies that pose unique challenges in terms of diagnosis, treatment, and understanding of the underlying molecular pathogenetic mechanisms. Erythropoietin-producing hepatocellular receptors (EPHs), the largest family of receptor tyrosine kinases and their membrane-tethered ligands, ephrins, orchestrate short-distance cell–cell signaling and are intricately involved in cell-pattern morphogenesis and various developmental processes. Unraveling the role of the EPH/ephrin signaling pathway in the pathophysiology of pediatric neoplasms and its clinical implications can contribute to deciphering the intricate landscape of these malignancies. The bidirectional nature of the EPH/ephrin axis is underscored by emerging evidence revealing its capacity to drive tumorigenesis, fostering cell–cell communication within the tumor microenvironment. In the context of carcinogenesis, the EPH/ephrin signaling pathway prompts a reevaluation of treatment strategies, particularly in pediatric oncology, where the modest progress in survival rates and enduring treatment toxicity necessitate novel approaches. Molecularly targeted agents have emerged as promising alternatives, prompting a shift in focus. Through a nuanced understanding of the pathway’s intricacies, we aim to lay the groundwork for personalized diagnostic and therapeutic strategies, ultimately contributing to improved outcomes for young patients grappling with neoplastic challenges. Full article
Show Figures

Figure 1

Back to TopTop